Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  NASDAQ OMX COPENHAGEN  >  ALK-Abello A/S    ALK B   DK0060027142

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

ALK-Abello A/S : Grant of share options and conditional shares to members of the Board of Management and key employees

share with twitter share with LinkedIn share with facebook
share via e-mail
0
05/11/2012 | 10:19am CEST

Copenhagen, 2012-05-11 08:55 CEST (GLOBE NEWSWIRE) --

Share option programme
According to the guidelines for incentive pay adopted at the Company's annual general meeting on 27 March 2012, the Board of Directors has passed a resolution to grant a total of 101,000 share options, comprising 40,250 options to the members of the Board of Management and 60,750 options to a group of key employees.

The options can be exercised during the period from 1 May 2015 to 1 May 2019 during the four-week trading windows following the release of annual and interim reports. If the option holders have not exercised their options within the period specified, the options will lapse without any compensation to the holders.

The exercise price of the options has been set at DKK 399 each, corresponding to an average of the closing prices of the company's shares on the NASDAQ OMX Copen­hagen A/S during the period 2 - 9 May 2012 (both days included). To this should be added annual interest at the rate of 2.5%, which will be added the first time on 1 May 2013. The exercise price of the options will be adjusted on payment of dividend, to the effect that DKK 1 of dividend per share results in a reduction of the exercise price by DKK 1.

The market value of the adopted option plan of 101,000 options is approximately DKK 6 million applying the Black & Scholes model for valuation of options. The determination of the value is based on an assumed exercise price of DKK 440, an annual dividend distribution of DKK 5 per share, a volatility rate of 22% p.a. and a risk-free interest rate of 1.49% p.a.

Conditional share programme
The Board of Directors has passed a resolution to grant conditional shares in accordance with the guidelines for incentive pay adopted at the Company's annual general meeting. The scheme comprises a total of 15,300 conditional shares, including 6,100 shares to the members of the Board of Management and 9,200 shares to a group of key employees. The market value of the conditional shares is approximately DKK 6 million, calculated on the basis of an average of the closing prices of the company's shares on the NASDAQ OMX Copenhagen A/S during the period 2 - 9 May 2012 (both days included).

Conditional shares will be available in May 2015, three years following the date of grant, provided that ALK achieves the financial targets for vesting and that the employment relationship with the ALK Group has not been terminated by the Company on objective grounds or terminated during the three-year period from the date of grant in 2012.

Under the international financial reporting standards (IFRS), the incentive plans will be recognised in the income statement in the respective functional areas over the vesting period.

The grant of share options and conditional shares does not change the company's financial forecast.

No share options or conditional shares have been granted to members of the Board of Directors.



ALK-Abelló A/S

Steen Riisgaard
Chairman

For further information please contact:
Steen Riisgaard, Chairman of the Board of Directors, tel +45 4446 0000



distributed by
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ALK-ABELLO A/S
05/10 Epinephrine Autoinjector Market 2017 - Mylan, Sanofi, Impax, ALK Abello
05/04ALK-ABELLO A/S : quaterly earnings release
03/23 ALK ABELLO A/S : Report on Management's transactions with ALK-Abelló A/S B share..
03/23 ALK ABELLO A/S : Grant of share options and performance shares to members of the..
03/16 ALK ABELLO A/S : Report on transactions with ALK-Abelló A/S B-shares and associa..
03/16 ALK-ABELLO A/S : ex-dividend day for annual dividend
03/15 ALK ABELLO A/S : Annual General Meeting in ALK-Abelló A/S held on 15 March 2017
03/06 ALK ABELLO A/S : Report on transactions with ALK-Abelló A/S B-shares and associa..
03/03 ALK ABELLO A/S : appoints SVP of R&D for North America and International Markets
02/02ALK-ABELLO A/S : annual earnings release
More news
Sector news : Pharmaceuticals - NEC
06/23DJSAMSUNG ELECTRONICS : Makes Play for Drug Market With Version of Humira -- Updat..
06/23DJSAMSUNG ELECTRONICS : Makes Big Play in Drug Market With Cheaper Version of Bloc..
06/23DJOne of the Last Untapped Blockbuster Diseases? Drug Companies Race to Find a ..
06/23 China's ICBC says checks of loans to big acquirers are routine
06/22 GSK'S NEW CEO AIMS TO DIVEST SPORTS : sources
More sector news : Pharmaceuticals - NEC
Advertisement
Financials ( DKK)
Sales 2017 2 974 M
EBIT 2017 156 M
Net income 2017 70,0 M
Debt 2017 97,5 M
Yield 2017 0,46%
P/E ratio 2017 116,04
P/E ratio 2018 54,56
EV / Sales 2017 3,14x
EV / Sales 2018 2,84x
Capitalization 9 226 M
More Financials
Chart ALK-ABELLO A/S
Duration : Period :
ALK-Abello A/S Technical Analysis Chart | ALK B | DK0060027142 | 4-Traders
Full-screen chart
Technical analysis trends ALK-ABELLO A/S
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus UNDERPERFORM
Number of Analysts 7
Average target price 987  DKK
Spread / Average Target -1,5%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Carsten Hellmann President & Chief Executive Officer
Steen Riisgaard Chairman
Flemming Pedersen CFO, EVP-Finance, IT, IR & Business Development
Henrik Hugo Jacobi Executive Vice President-Research & Development
Anders Gersel Pedersen Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
ALK-ABELLO A/S11.30%1 386
JOHNSON & JOHNSON18.42%367 520
NOVARTIS13.09%225 386
ROCHE HOLDING LTD.8.68%224 497
PFIZER5.20%203 487
MERCK AND COMPANY12.38%180 958
More Results